Welcome to our dedicated page for Halberd news (Ticker: HALB), a resource for investors and traders seeking the latest updates and insights on Halberd stock.
Halberd Corporation (HALB) is an innovative biopharmaceutical company developing targeted therapies for PTSD, traumatic brain injury, and related mental health conditions through patented drug formulations and wearable monitoring technologies. This news hub provides investors and researchers with timely updates on the company's clinical trials, intellectual property developments, and strategic partnerships.
Access authoritative information about HALB's progress in mental health treatment innovation, including updates on its LDN+ and Tri-Ax nasal spray therapies. The repository consolidates press releases related to CRADA clinical trials, technology integrations with partners like Athena GTX, and patent filings that underpin the company's valuation.
Key content categories include regulatory milestones, research collaborations with military healthcare providers, and advancements in combined pharmaceutical/digital health solutions. All materials maintain compliance with OTC Market disclosure standards while emphasizing HALB's unique position at the intersection of biopharma and wearable diagnostics.
Bookmark this page for streamlined tracking of HALB's progress in addressing critical mental health challenges through evidence-based therapeutic innovation. Check regularly for verified updates that reflect the company's commitment to advancing both patient care and shareholder value.
Halberd, Inc. (HALB) has achieved significant progress in its latest laboratory tests, successfully eliminating Beta Amyloid and Interleukin-4 from synthetic cerebrospinal fluid (CSF). This accomplishment aligns with HALB's objective to manage key antigens associated with neurodegenerative diseases such as Alzheimer's, PTSD, and ALS. The company has completed eradication tests for multiple target antigens and boasts three issued patents related to this technology. CEO William A. Hartman emphasized the uniqueness of HALB's approach compared to competitors, which reportedly eliminate only a fraction of Beta Amyloid.
Halberd Corporation (OTC PINK:HALB) is now registered with the Federal Government's System for Award Management, enabling it to bid on Federal contracts in biotechnology research and health supplements. This opens opportunities to serve military members and government agencies addressing neurodegenerative diseases like PTSD, Alzheimer's, and more. The company claims proof-of-concept for removing disease-related antigens from cerebral spinal fluid and plans to advance to in-vivo studies. Halberd has secured three patents and filed numerous applications to boost its market presence.
Halberd Corporation (OTC Pink: HALB) has successfully eliminated Interleukin-2 (IL-2) from synthetic cerebral spinal fluid (CSF) in preliminary tests. IL-2, a pro-inflammatory cytokine, is linked to neurodegeneration and neuroprotection in conditions like Alzheimer's Disease. Dr. Mitchell S. Felder emphasized this ability could halt Alzheimer's progression when combined with controls on other inflammatory cytokines. CEO William A. Hartman stated that this technology could revolutionize treatment for various neurodegenerative diseases and may lead to breakthroughs for related diseases like cancer.
Halberd Corporation (OTC PINK:HALB) announced a breakthrough in its ongoing research, achieving 100% eradication of Interleukin-12 (IL-12) from synthetic cerebral spinal fluid. This pro-inflammatory cytokine has been linked with Alzheimer's Disease, affecting over 6 million people in the U.S. and 40 million worldwide. CEO William A. Hartman mentions this technology aims to eliminate antigens related to neurodegenerative diseases, positioning Halberd as a unique player in this field. The company's future plans include promoting this technology to target conditions like Traumatic Brain Injury and PTSD.
Halberd Corporation (OTC PINK:HALB) announced a breakthrough achievement in neuroscience by successfully eradicating Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF) during preliminary testing. This advancement is critical, as IL-1 is linked to various severe diseases including Alzheimer's and Multiple Sclerosis. The company's patented technology has previously eliminated other inflammatory cytokines, enhancing prospects for treating neurodegenerative conditions. Halberd aims to revolutionize treatments for diseases such as Alzheimer’s and Parkinson’s through ongoing research and patent protections.
Halberd Corporation (OTC PINK:HALB) has announced successful verification tests demonstrating a 100% elimination of Tumor Necrosis Factor-alpha (TNF-alpha) from synthetic cerebral spinal fluid (CSF). This breakthrough, achieved through their patented process and laser irradiation, indicates potential new treatments for conditions like Alzheimer's Disease and PTSD. The company also highlighted previous success in eliminating Phosphorylated Tau and Interleukin 6, emphasizing ongoing research to address other inflammatory markers associated with neurodegenerative diseases.
Halberd Corporation (OTC PINK:HALB) announced a significant breakthrough in treating Alzheimer's Disease by eradicating 85% of Tumor Necrosis Factor-alpha (TNF-α) from synthetic cerebral spinal fluid (CSF) using its patented process and laser technology. This inflammatory cytokine is linked to the progression of Alzheimer's and obesity. The company aims to continue its research on eliminating other markers associated with neurodegenerative diseases. Halberd holds exclusive worldwide rights to multiple patents, enhancing its potential value for shareholders.
Halberd Corporation (OTC PINK:HALB) has filed a non-provisional patent application for a novel extracorporeal treatment targeting Covid-19 via radio frequency waves. This follows a provisional application and aims to enhance Halberd's intellectual property rights. The treatment uses a proprietary SARS-CoV-2 antibody attached to gold-coated iron nanoparticles, which, when exposed to radio frequency, neutralizes the virus. Halberd's Chairman emphasizes that while the focus remains on neurological diseases, this patent could increase scientific value.
Halberd Corporation (OTC PINK:HALB) has achieved a significant milestone by eliminating 100% of IL-6 from synthetic cerebrospinal fluid (CSF) during preliminary testing. Utilizing its patented extracorporeal and patent-pending laser eradication processes, IL-6 was eradicated in as little as three minutes. Elevated IL-6 levels are linked to neurological disorders, including PTSD, Chronic Traumatic Encephalopathy, and Alzheimer's Disease. The company plans to continue research towards eliminating other inflammatory cytokines and pursuing military endorsement for its advancements.
Halberd Corporation (OTC PINK:HALB) has filed a provisional patent application for a new process aimed at removing obesity-related proteins, cytokines, and antigens from patients' blood. This innovative approach may help alleviate severe health issues linked to obesity. The research builds on previous work in treating PTSD and Alzheimer's Disease, suggesting a potential connection between inflammatory cytokines and obesity. The treatment process is designed to be as straightforward as blood donation, with expected completion times of 30-60 minutes.
FAQ
What is the current stock price of Halberd (HALB)?
What is the market cap of Halberd (HALB)?
